Open6.32

High6.45

Low5.84

Volume1.61M

Average Volume607169.00

P/E-

Forward P/E-2.40

Market cap46.12M

52W H16.25

52W L3.50

Beta0.90

Dividend yield-

Open

High

Low

Volume

Average Volume

P/E

Forward P/E

Market cap

52W H

52W L

Beta

Dividend yield

Radiopharm Theranostics Limited

Radiopharm Theranostics Limited a clinical-stage radiotherapeutics company, engages in the research and development of radiopharmaceutical products for diagnostic and therapeutic uses in areas with high unmet medical needs. The company develops several products, including RAD101, a pivalate brain metastasis diagnostic; RAD102, a pivalate therapeutic; RAD201a, a Nano-mAb HER-2 breast diagnostic; RAD202, a Nano-mAb HER-2 breast therapeutic; RAD203, a Nano-mAb PDL1 non-small cell lung diagnostic; and RAD204, a Nano-mAb PDL1 non-small cell lung therapeutic. Additionally, it is developing RAD301 and RAD302, which are Avß6-Integrin pancreatic diagnostic and therapeutic products; RAD401, a PSA-mAb prostate cancer diagnostic; RAD402, a PSA-mAb prostate cancer therapeutic; RAD601, a PTPµ glioblastoma diagnostic; and RAD602, a PTPµ glioblastoma therapeutic. The company has a strategic agreement with Lantheus Holdings, Inc. to advance the clinical development of radiopharmaceuticals. The company was incorporated in 2021 and is based in Carlton, Australia.

Websitehttps://www.radiopharmtheranostics.com

SectorHealthcare

IndustryBiotechnology

Number of employees

14

Short term outlookBearish

Long term outlookBearish

Website

Sector

Industry

Number of employees

Short term outlook

Long term outlook

News:

Top Premarket Decliners
MT Newswires
•
2 hours ago
Radiopharm (RADX) Sees Slight Pessimism From Analysts
Insider Monkey
•
22 hours ago
Top Midday Gainers
MT Newswires
•
22 hours ago
Radiopharm's Phase 2b Trial of RAD 101 Achieves Primary Endpoint in 11 Patients Based on Interim Data; Shares Surge Pre-Bell
MT Newswires
•
1 day and 3 hours ago
Top Premarket Gainers
MT Newswires
•
1 day and 3 hours ago

RADX

Close price of for each day

Include open price

Top Premarket Decliners
MT Newswires
•
2 hours ago
Radiopharm (RADX) Sees Slight Pessimism From Analysts
Insider Monkey
•
22 hours ago
Top Midday Gainers
MT Newswires
•
22 hours ago
Radiopharm's Phase 2b Trial of RAD 101 Achieves Primary Endpoint in 11 Patients Based on Interim Data; Shares Surge Pre-Bell
MT Newswires
•
1 day and 3 hours ago
Top Premarket Gainers
MT Newswires
•
1 day and 3 hours ago

Open6.32

High6.45

Low5.84

Volume1.61M

Average Volume607169.00

P/E-

Forward P/E-2.40

Market cap46.12M

52W H16.25

52W L3.50

Beta0.90

Dividend yield-

Radiopharm Theranostics Limited

Radiopharm Theranostics Limited a clinical-stage radiotherapeutics company, engages in the research and development of radiopharmaceutical products for diagnostic and therapeutic uses in areas with high unmet medical needs. The company develops several products, including RAD101, a pivalate brain metastasis diagnostic; RAD102, a pivalate therapeutic; RAD201a, a Nano-mAb HER-2 breast diagnostic; RAD202, a Nano-mAb HER-2 breast therapeutic; RAD203, a Nano-mAb PDL1 non-small cell lung diagnostic; and RAD204, a Nano-mAb PDL1 non-small cell lung therapeutic. Additionally, it is developing RAD301 and RAD302, which are Avß6-Integrin pancreatic diagnostic and therapeutic products; RAD401, a PSA-mAb prostate cancer diagnostic; RAD402, a PSA-mAb prostate cancer therapeutic; RAD601, a PTPµ glioblastoma diagnostic; and RAD602, a PTPµ glioblastoma therapeutic. The company has a strategic agreement with Lantheus Holdings, Inc. to advance the clinical development of radiopharmaceuticals. The company was incorporated in 2021 and is based in Carlton, Australia.

Websitehttps://www.radiopharmtheranostics.com

SectorHealthcare

IndustryBiotechnology

Number of employees

14

Short term outlookBearish

Long term outlookBearish

Stock.io

Radiopharm Theranostics Limited

Radiopharm Theranostics Limited